SCHEMBL22728769

SCHEMBL22728769

COC(=O)C(C=O)CC(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 6/20 0.44
▸ HDAC1 Q13547 6/20 0.44
▸ HDAC2 Q92769 6/20 0.44
▸ HDAC4 P56524 5/20 0.44
▸ HDAC7 Q8WUI4 5/20 0.44
▸ HDAC10 Q969S8 5/20 0.44
▸ HDAC11 Q96DB2 5/20 0.44
▸ HDAC8 Q9BY41 5/20 0.44
▸ HDAC6 Q9UBN7 5/20 0.44
▸ HDAC9 Q9UKV0 5/20 0.44
▸ HDAC5 Q9UQL6 5/20 0.44
▸ HPGD P15428 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MMP2 P08253 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MMP8 P22894 1/20 0.43
▸ VNN1 O95497 1/20 0.42
▸ EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19660155 0.85 HDAC8 (0.50) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL19660200 0.83 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL22728863 0.83 ALOX15 (0.47) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL23797019 0.80 L3MBTL1 (0.55) HPGDALDH1A1SMN1; SMN2KMT2APOLB
SCHEMBL21654210 0.77 MMP2 (0.50) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL17290763 0.74 HDAC3 (0.52) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL19642557 0.74 MMP2 (0.47) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL16563628 0.72 MMP2 (0.51) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL5747073 0.72 HDAC3 (0.45) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL6141283 0.72 HDAC3 (0.54) HDAC3HDAC1HDAC2HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3580211-B1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER BAYER AG (DE) 2020-12-02 — — EP disclosed
Send feedback